Company updateMoneycontrol
Geojit raises Aurobindo Pharma target to Rs 2111
Positive+59
GreyOak summary
Geojit Financial Services retained its BUY rating on Aurobindo Pharma with a revised target price of Rs 2,111. The company reported Q2FY27 revenue growth of 23.9% to Rs 10,263cr, driven by strong performance in formulations and APIs. EBITDA increased 28.5% to Rs 2,156cr with margins expanding to 21.0%.
What it affects
- Aurobindo PharmaAUROPHARMAPositive +59
Revenue grew 23.9% to Rs 10,263crRolling sentiment Negative -18
Source
Read the original at MoneycontrolMore Aurobindo Pharma news
- Aurobindo Pharma shares extend losses after USFDA OAICNBC-TV18 · Regulatory ·
- Buzzing stocks: Bajaj Finance, Tata Power, Adani Enterprises, Sandur Manganese, Alivus Life, Aurobindo PharmaBusinessLine · Company update ·
- Stocks to watch today, Nov 12: Tata Power, Hindustan Copper, Bajaj Finance, and moreFinancial Express · Results ·
- Stocks in news: Tata Power, Cupid, Garden Reach, ITC, Aurobindo Pharma and Vodafone IdeaEconomic Times · Results ·
- USFDA classifies Aurobindo Pharma's US facility as 'official action indicated'Economic Times · Regulatory ·